Efficacy and safety of tacrolimus compared with ciclosporin a in renal transplantation: Three-year observational results

Bernhard K. Krämer, Domingo Del Castillo, Raimund Margreiter, Heide Sperschneider, Christoph J. Olbricht, Joaquín Ortuño, Urban Sester, Ulrich Kunzendorf, Karl Heinz Dietl, Vittorio Bonomini, Paolo Rigotti, Claudio Ronco, Jose M. Tabernero, Manuel Rivero, Bernhard Banas, Ferdinand Mühlbacher, Manuel Arias, Giuseppe Montagnino

Research output: Contribution to journalArticle

Abstract

Background. The European tacrolimus versus ciclosporin A microemulsion (CsA-ME) renal transplantation study showed that tacrolimus was significantly more effective in preventing acute rejection and had a superior cardiovascular risk profile at 6 months. Methods. The endpoints of this investigator-initiated, observational, 36-month follow-up were acute rejection incidence rates, rates of patient and graft survival and renal function. An additional analysis was performed using the combined endpoints BPAR, graft loss and patient death. Data available from the original ITT population (557 patients; 286 tacrolimus and 271 CsA-ME) were analysed. Results. A total of 231 tacrolimus and 217 CsA-ME patients participated. At 36 months, Kaplan-Meier-estimated BPAR-free survival rates were 78.8% in the tacrolimus group and 60.6% in the CsA-ME group, graft survival rates were 88.0% and 86.9% and patient survival rates were 96.6% and 96.7%, respectively. The estimated combined endpoint-free survival rate was 71.4% with tacrolimus and 55.4% with CsA-ME (P ≤ 0.001, chi-square test). Significantly more CsA-ME patients crossed over to tacrolimus during the 3-year follow-up: 21.2% versus 2.6%, P ≤ 0.0001, chi-square test. Most patients in the tacrolimus arm discontinued steroids and received monotherapy and fewer tacrolimus patients remained on a triple regimen. Mean serum creatinine concentration was 145.4 ± 90.9 μmol/L with tacrolimus and 149.0 ± 92.1 μmol/L with CsA-ME. Significantly more CsA-ME patients had a classified cholesterol value >6 mmol/L (26.3% versus 12.6%, P ≤ 0.0003, chi-square test). Conclusions. Patients treated with tacrolimus had significantly higher combined endpoint-free survival rates and lower acute rejection rates with less immunosuppressive medication at 36 months.

Original languageEnglish
Pages (from-to)2386-2392
Number of pages7
JournalNephrology Dialysis Transplantation
Volume23
Issue number7
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Tacrolimus
Kidney Transplantation
Cyclosporine
Safety
Survival Rate
Chi-Square Distribution
Graft Survival
Immunosuppressive Agents
Creatinine
Arm
Steroids
Cholesterol
Research Personnel
Transplants
Kidney

Keywords

  • Acute rejection
  • Calcineurin inhibitors
  • Follow-up
  • Graft survival
  • Patient survival

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Krämer, B. K., Del Castillo, D., Margreiter, R., Sperschneider, H., Olbricht, C. J., Ortuño, J., ... Montagnino, G. (2008). Efficacy and safety of tacrolimus compared with ciclosporin a in renal transplantation: Three-year observational results. Nephrology Dialysis Transplantation, 23(7), 2386-2392. https://doi.org/10.1093/ndt/gfn004

Efficacy and safety of tacrolimus compared with ciclosporin a in renal transplantation : Three-year observational results. / Krämer, Bernhard K.; Del Castillo, Domingo; Margreiter, Raimund; Sperschneider, Heide; Olbricht, Christoph J.; Ortuño, Joaquín; Sester, Urban; Kunzendorf, Ulrich; Dietl, Karl Heinz; Bonomini, Vittorio; Rigotti, Paolo; Ronco, Claudio; Tabernero, Jose M.; Rivero, Manuel; Banas, Bernhard; Mühlbacher, Ferdinand; Arias, Manuel; Montagnino, Giuseppe.

In: Nephrology Dialysis Transplantation, Vol. 23, No. 7, 07.2008, p. 2386-2392.

Research output: Contribution to journalArticle

Krämer, BK, Del Castillo, D, Margreiter, R, Sperschneider, H, Olbricht, CJ, Ortuño, J, Sester, U, Kunzendorf, U, Dietl, KH, Bonomini, V, Rigotti, P, Ronco, C, Tabernero, JM, Rivero, M, Banas, B, Mühlbacher, F, Arias, M & Montagnino, G 2008, 'Efficacy and safety of tacrolimus compared with ciclosporin a in renal transplantation: Three-year observational results', Nephrology Dialysis Transplantation, vol. 23, no. 7, pp. 2386-2392. https://doi.org/10.1093/ndt/gfn004
Krämer, Bernhard K. ; Del Castillo, Domingo ; Margreiter, Raimund ; Sperschneider, Heide ; Olbricht, Christoph J. ; Ortuño, Joaquín ; Sester, Urban ; Kunzendorf, Ulrich ; Dietl, Karl Heinz ; Bonomini, Vittorio ; Rigotti, Paolo ; Ronco, Claudio ; Tabernero, Jose M. ; Rivero, Manuel ; Banas, Bernhard ; Mühlbacher, Ferdinand ; Arias, Manuel ; Montagnino, Giuseppe. / Efficacy and safety of tacrolimus compared with ciclosporin a in renal transplantation : Three-year observational results. In: Nephrology Dialysis Transplantation. 2008 ; Vol. 23, No. 7. pp. 2386-2392.
@article{63c1dc11883a4fec86f8f10c6df9fb04,
title = "Efficacy and safety of tacrolimus compared with ciclosporin a in renal transplantation: Three-year observational results",
abstract = "Background. The European tacrolimus versus ciclosporin A microemulsion (CsA-ME) renal transplantation study showed that tacrolimus was significantly more effective in preventing acute rejection and had a superior cardiovascular risk profile at 6 months. Methods. The endpoints of this investigator-initiated, observational, 36-month follow-up were acute rejection incidence rates, rates of patient and graft survival and renal function. An additional analysis was performed using the combined endpoints BPAR, graft loss and patient death. Data available from the original ITT population (557 patients; 286 tacrolimus and 271 CsA-ME) were analysed. Results. A total of 231 tacrolimus and 217 CsA-ME patients participated. At 36 months, Kaplan-Meier-estimated BPAR-free survival rates were 78.8{\%} in the tacrolimus group and 60.6{\%} in the CsA-ME group, graft survival rates were 88.0{\%} and 86.9{\%} and patient survival rates were 96.6{\%} and 96.7{\%}, respectively. The estimated combined endpoint-free survival rate was 71.4{\%} with tacrolimus and 55.4{\%} with CsA-ME (P ≤ 0.001, chi-square test). Significantly more CsA-ME patients crossed over to tacrolimus during the 3-year follow-up: 21.2{\%} versus 2.6{\%}, P ≤ 0.0001, chi-square test. Most patients in the tacrolimus arm discontinued steroids and received monotherapy and fewer tacrolimus patients remained on a triple regimen. Mean serum creatinine concentration was 145.4 ± 90.9 μmol/L with tacrolimus and 149.0 ± 92.1 μmol/L with CsA-ME. Significantly more CsA-ME patients had a classified cholesterol value >6 mmol/L (26.3{\%} versus 12.6{\%}, P ≤ 0.0003, chi-square test). Conclusions. Patients treated with tacrolimus had significantly higher combined endpoint-free survival rates and lower acute rejection rates with less immunosuppressive medication at 36 months.",
keywords = "Acute rejection, Calcineurin inhibitors, Follow-up, Graft survival, Patient survival",
author = "Kr{\"a}mer, {Bernhard K.} and {Del Castillo}, Domingo and Raimund Margreiter and Heide Sperschneider and Olbricht, {Christoph J.} and Joaqu{\'i}n Ortu{\~n}o and Urban Sester and Ulrich Kunzendorf and Dietl, {Karl Heinz} and Vittorio Bonomini and Paolo Rigotti and Claudio Ronco and Tabernero, {Jose M.} and Manuel Rivero and Bernhard Banas and Ferdinand M{\"u}hlbacher and Manuel Arias and Giuseppe Montagnino",
year = "2008",
month = "7",
doi = "10.1093/ndt/gfn004",
language = "English",
volume = "23",
pages = "2386--2392",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Efficacy and safety of tacrolimus compared with ciclosporin a in renal transplantation

T2 - Three-year observational results

AU - Krämer, Bernhard K.

AU - Del Castillo, Domingo

AU - Margreiter, Raimund

AU - Sperschneider, Heide

AU - Olbricht, Christoph J.

AU - Ortuño, Joaquín

AU - Sester, Urban

AU - Kunzendorf, Ulrich

AU - Dietl, Karl Heinz

AU - Bonomini, Vittorio

AU - Rigotti, Paolo

AU - Ronco, Claudio

AU - Tabernero, Jose M.

AU - Rivero, Manuel

AU - Banas, Bernhard

AU - Mühlbacher, Ferdinand

AU - Arias, Manuel

AU - Montagnino, Giuseppe

PY - 2008/7

Y1 - 2008/7

N2 - Background. The European tacrolimus versus ciclosporin A microemulsion (CsA-ME) renal transplantation study showed that tacrolimus was significantly more effective in preventing acute rejection and had a superior cardiovascular risk profile at 6 months. Methods. The endpoints of this investigator-initiated, observational, 36-month follow-up were acute rejection incidence rates, rates of patient and graft survival and renal function. An additional analysis was performed using the combined endpoints BPAR, graft loss and patient death. Data available from the original ITT population (557 patients; 286 tacrolimus and 271 CsA-ME) were analysed. Results. A total of 231 tacrolimus and 217 CsA-ME patients participated. At 36 months, Kaplan-Meier-estimated BPAR-free survival rates were 78.8% in the tacrolimus group and 60.6% in the CsA-ME group, graft survival rates were 88.0% and 86.9% and patient survival rates were 96.6% and 96.7%, respectively. The estimated combined endpoint-free survival rate was 71.4% with tacrolimus and 55.4% with CsA-ME (P ≤ 0.001, chi-square test). Significantly more CsA-ME patients crossed over to tacrolimus during the 3-year follow-up: 21.2% versus 2.6%, P ≤ 0.0001, chi-square test. Most patients in the tacrolimus arm discontinued steroids and received monotherapy and fewer tacrolimus patients remained on a triple regimen. Mean serum creatinine concentration was 145.4 ± 90.9 μmol/L with tacrolimus and 149.0 ± 92.1 μmol/L with CsA-ME. Significantly more CsA-ME patients had a classified cholesterol value >6 mmol/L (26.3% versus 12.6%, P ≤ 0.0003, chi-square test). Conclusions. Patients treated with tacrolimus had significantly higher combined endpoint-free survival rates and lower acute rejection rates with less immunosuppressive medication at 36 months.

AB - Background. The European tacrolimus versus ciclosporin A microemulsion (CsA-ME) renal transplantation study showed that tacrolimus was significantly more effective in preventing acute rejection and had a superior cardiovascular risk profile at 6 months. Methods. The endpoints of this investigator-initiated, observational, 36-month follow-up were acute rejection incidence rates, rates of patient and graft survival and renal function. An additional analysis was performed using the combined endpoints BPAR, graft loss and patient death. Data available from the original ITT population (557 patients; 286 tacrolimus and 271 CsA-ME) were analysed. Results. A total of 231 tacrolimus and 217 CsA-ME patients participated. At 36 months, Kaplan-Meier-estimated BPAR-free survival rates were 78.8% in the tacrolimus group and 60.6% in the CsA-ME group, graft survival rates were 88.0% and 86.9% and patient survival rates were 96.6% and 96.7%, respectively. The estimated combined endpoint-free survival rate was 71.4% with tacrolimus and 55.4% with CsA-ME (P ≤ 0.001, chi-square test). Significantly more CsA-ME patients crossed over to tacrolimus during the 3-year follow-up: 21.2% versus 2.6%, P ≤ 0.0001, chi-square test. Most patients in the tacrolimus arm discontinued steroids and received monotherapy and fewer tacrolimus patients remained on a triple regimen. Mean serum creatinine concentration was 145.4 ± 90.9 μmol/L with tacrolimus and 149.0 ± 92.1 μmol/L with CsA-ME. Significantly more CsA-ME patients had a classified cholesterol value >6 mmol/L (26.3% versus 12.6%, P ≤ 0.0003, chi-square test). Conclusions. Patients treated with tacrolimus had significantly higher combined endpoint-free survival rates and lower acute rejection rates with less immunosuppressive medication at 36 months.

KW - Acute rejection

KW - Calcineurin inhibitors

KW - Follow-up

KW - Graft survival

KW - Patient survival

UR - http://www.scopus.com/inward/record.url?scp=46849087558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46849087558&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfn004

DO - 10.1093/ndt/gfn004

M3 - Article

C2 - 18258740

AN - SCOPUS:46849087558

VL - 23

SP - 2386

EP - 2392

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 7

ER -